Neuropsychiatric reaction to treprostinil in pulmonary hypertension leading to treatment discontinuation.

A patient presented with dyspnoea and was subsequently diagnosed with pulmonary hypertension. Intravenous treprostinil was initiated as part of the treatment plan. Shortly after starting therapy, the patient developed new-onset restlessness and agitation, which progressively worsened in correlation with dose escalation.

Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights.

: Sotatercept has demonstrated efficacy in pulmonary arterial hypertension (PAH), but its use has not been studied in patients with Group 3 pulmonary hypertension (PH). Additionally, patients with connective tissue disease-associated PAH (CTD-PAH) were underrepresented in the STELLAR trial. Given the limited treatment options for pulmonary hypertension in patients with interstitial lung disease (PH-ILD), this study aimed to evaluate the use of sotatercept in CTD-PAH patients with concomitant ILD.

Level 3 Cardiopulmonary Exercise Testing to Guide Therapeutic Decisions in Non-Severe Pulmonary Hypertension with Lung Disease.

Inhaled treprostinil is approved for the treatment of pulmonary hypertension-associated interstitial lung disease (PH-ILD); however, it has not shown significant benefit in patients with a pulmonary vascular resistance (PVR) < 4 WU. As such, treatment for non-severe PH-ILD remains controversial. A total of 16 patients with non-severe PH-ILD were divided into two groups based on changes in PVR during exercise: a dynamic PVR group ( = 10), characterized by an increase in PVR with exertion, and a static PVR group ( = 6), with no increase in PVR with exercise.

Efficacy and Safety of Selexipag Treatment in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease.

Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and concomitant interstitial lung disease (ILD) are particularly challenging to manage due to concerns about ventilation-perfusion mismatch with systemic vasodilators. In this case series, we evaluated the effects of selexipag in eight prostacyclin-naïve CTD-PAH patients with concomitant ILD. Clinical, functional, and laboratory data were collected at baseline and after 16 weeks of treatment.

The Impact of Glycemic Control on Ranibizumab Efficacy in Diabetic Retinopathy: A Retrospective Analysis.

Background:  Diabetic retinopathy (DR), a leading cause of vision loss, is driven by inflammation, oxidative stress, and vascular endothelial growth factor (VEGF) production, with elevated blood glucose and advanced glycation end products (AGEs) exacerbating retinal damage. While intravitreal VEGF inhibitors have become the first-line treatment for diabetic macular edema (DME), response to therapy varies due to systemic factors such as HbA1c levels, blood pressure, and diabetes duration.

Objectives: This study aims to assess the impact of glycosylated hemoglobin (HbA1c) control on the effectiveness of Ranibizumab treatment in patients with DR.